2-氯-6-甲基吡啶-4-硼酸频哪醇酯 | 697739-22-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氯-6-甲基吡啶-4-硼酸频哪醇酯
• 英文名称: 2-chloro-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
• CAS: 697739-22-3
• 化学式: C₁₂H₁₇BClNO₂
• 分子量: 253.536
• InChiKey: CDNAAWYZHQPEAX-UHFFFAOYSA-N

物化性质

• 沸点：
  354.1±42.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.34
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  温度：2-8°C，保持惰性气氛。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-6-methylpyridine-4-boronic acid, pinacol ester
Synonyms: 2-Chloro-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-6-methylpyridine-4-boronic acid, pinacol ester
CAS number: 697739-22-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H17BClNO2
Molecular weight: 253.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-6-甲基吡啶-4-硼酸频哪醇酯 在 chloroamine-T 、 sodium iodide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 以68%的产率得到2-氯-4-碘-6-甲基吡啶
  参考文献：
  名称：

  Synthetic Route Design of AZD4635, an A_2AR Antagonist

  摘要：

  The AstraZeneca approach to synthetic Route Design is exemplified through our AZD4635 chemical development program. The identification of possible new route concepts is presented, as well as their subsequent prioritization for practical exploration based on project objectives. Selected ideas were tested to demonstrate proof of concept for the bond formation strategy and, where successful, were fed into a decision tool based on key SELECTion principles.

  DOI：

  10.1021/acs.oprd.9b00171
• 作为产物：
  描述：

  2-甲基-6-氯吡啶 以94的产率得到2-氯-6-甲基吡啶-4-硼酸频哪醇酯
  参考文献：
  名称：

  [EN] 1,2,4-TRIAZINE-4-AMINE DERIVATIVES
  [FR] DÉRIVÉS DE 1,2,4-TRIAZINE-4-AMINE

  摘要：

  根据本发明提供了一种A1式化合物，该化合物可能在治疗通过抑制A1-A2b或特别是A2a受体而改善的疾病或障碍方面有用，其中A1式化合物具有以下结构，其中，A代表Cy1或HetA；Cy1代表一个5-至14-成员的芳香，完全饱和或部分不饱和的碳环系统，包括一个，两个或三个环，该Cy1基团可以被一个或多个R4a取代；HetA代表一个5-至14-成员的杂环基团，该杂环基团可以是芳香，完全饱和或部分不饱和，并且其中包含一个或多个从O，S和N中选择的杂原子，该杂环基团可以包括一个，两个或三个环，该HetA基团可以被一个或多个R4b取代；B代表Cy2或HetB；Cy2代表一个3-至10-成员的芳香，完全饱和或部分不饱和的碳环系统，包括一个或两个环，该Cy2基团可以被一个或多个R4c取代；HetB代表一个3-至10-成员的杂环基团，该杂环基团可以是芳香，完全饱和或部分不饱和，并且其中包含一个或多个从O，S和N中选择的杂原子，该杂环基团可以包括一个或两个环，该HetB基团可以被一个或多个R4d取代。

  公开号：

  WO2011095625A1
• 作为试剂：
  描述：

  2-氯-6-甲基吡啶-4-硼酸频哪醇酯 、 6-bromo-5-(4-fluorophenyl)-1,2,4-triazin-3-amine 在 2-氯-6-甲基吡啶-4-硼酸频哪醇酯 作用下， 以34.9的产率得到6-(2-氯-6-甲基-4-吡啶基)-5-(4-氟苯基)-1,2,4-三嗪-3-胺
  参考文献：
  名称：

  [EN] 1,2,4-TRIAZINE-4-AMINE DERIVATIVES
  [FR] DÉRIVÉS DE 1,2,4-TRIAZINE-4-AMINE

  摘要：

  根据本发明提供了一种A1式化合物，该化合物可能在治疗通过抑制A1-A2b或特别是A2a受体而改善的疾病或障碍方面有用，其中A1式化合物具有以下结构，其中，A代表Cy1或HetA；Cy1代表一个5-至14-成员的芳香，完全饱和或部分不饱和的碳环系统，包括一个，两个或三个环，该Cy1基团可以被一个或多个R4a取代；HetA代表一个5-至14-成员的杂环基团，该杂环基团可以是芳香，完全饱和或部分不饱和，并且其中包含一个或多个从O，S和N中选择的杂原子，该杂环基团可以包括一个，两个或三个环，该HetA基团可以被一个或多个R4b取代；B代表Cy2或HetB；Cy2代表一个3-至10-成员的芳香，完全饱和或部分不饱和的碳环系统，包括一个或两个环，该Cy2基团可以被一个或多个R4c取代；HetB代表一个3-至10-成员的杂环基团，该杂环基团可以是芳香，完全饱和或部分不饱和，并且其中包含一个或多个从O，S和N中选择的杂原子，该杂环基团可以包括一个或两个环，该HetB基团可以被一个或多个R4d取代。

  公开号：

  WO2011095625A1

文献信息

• [EN] 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER<br/>[FR] COMPOSÉS DE 5-AMINO-8-(4-FLUOROPHÉNYL)-[1,2,4]TRIAZOLO [4,3-C]PYRIMIDIN-3-ONE DESTINÉS À ÊTRE UTILISÉS CONTRE LE CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2021191379A1

  公开（公告）日：2021-09-30

  Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.

  本文描述了式（I）的三唑酮化合物及其药学上可接受的盐。还描述了制备和使用式（I）化合物的方法。式（I）的化合物及其药学上可接受的盐可用作腺苷受体拮抗剂，例如在治疗由腺苷受体介导的疾病或症状，如癌症、运动障碍或注意障碍方面。
• [EN] HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
  申请人：ARTIOS PHARMA LTD

  公开号：WO2021028643A1

  公开（公告）日：2021-02-18

  The application relates to heterocyclic amide derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation. (Formula (I))

  该申请涉及杂环酰胺衍生物及其在癌症治疗和预防中的应用，以及含有这些衍生物的组合物和其制备方法。(化学式(I))
• Microwave-assisted, Ir-catalyzed aromatic C–H borylation
  作者：Li Zeqing、Liang Zhibin、Wang Yuqiang、Yu Pei

  DOI：10.1007/s11164-012-0725-4

  日期：2013.4

  One-step conversions of 1,3-disubstituted benzenes to aryl boronates and 2,6-disubstituted pyridines to heteroaryl boronates are described. Microwave heating was used for all reactions. [(COD)Ir(μ-OMe)]2 and 4,4′-di-tert-butyl-2,2′-bipyridine were used as catalysts, in methyl tert-butyl ether. Acceleration of the rate of reaction was remarkable compared with that of same reaction under conventional heating conditions.

  一步法将1,3-二取代苯转化为芳基硼酸盐，以及将2,6-二取代吡啶转化为杂芳基硼酸盐的反应被描述。所有反应均采用微波加热。使用[(COD)Ir(μ-OMe)]2和4,4′-二叔丁基-2,2′-联吡啶作为催化剂，溶剂为甲基叔丁基醚。与传统加热条件下的相同反应相比，反应速率的加速效果显著。
• 三唑并嘧啶类衍生物、其制备方法及其在医药 上的应用
  申请人：江苏恒瑞医药股份有限公司

  公开号：CN109535161B

  公开（公告）日：2021-09-03

  本发明涉及三唑并嘧啶类衍生物、其制备方法及其在医药上的应用。具体而言，本发明涉及一种通式(I)所示的三唑并嘧啶类衍生物、其制备方法及含有该衍生物的药物组合物以及其作为治疗剂，特别是作为A2a受体拮抗剂的用途和在制备用于治疗通过对A2a受体的抑制而改善的病况或病症的药物中的用途，其中通式(I)的各取代基与说明书中的定义相同。
• [EN] 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE 1,8-NAPHTHYRIDINONE ET LEURS UTILISATIONS
  申请人：NUVATION BIO INC

  公开号：WO2020150676A1

  公开（公告）日：2020-07-23

  1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

  提供了作为腺苷受体调节剂的1,8-萘啶酮化合物。这些化合物可能作为治疗通过G蛋白偶联受体信号通路介导的疾病的治疗剂，并且可能在肿瘤学中发挥特定作用。